Non-alcoholic Fatty Liver Disease and Cardiovascular Disease Risk

Current Cardiovascular Risk Reports

Volumn 4, Issue 1, 2010, Pages 32-39

  Targher, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Cardiovascular disease; Metabolic syndrome; Non alcoholic fatty liver disease; Risk factors

Indexed keywords

EID: 84856744556     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-009-0070-3     Document Type: Article

References (50)

1. Adams LA, Lindor KD: Nonalcoholic fatty liver disease. Ann Epidemiol 2007, 17: 863-869.
2. • de Alwis NMW, Day CP: Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008, 48(Suppl 1): S104-S112. This is a comprehensive review on epidemiology, diagnosis, pathophysiology, clinical complications, and treatment of NAFLD.
3. • Kotronen A, Yki-Järvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28: 27-38. This elegant review summarizes the clinical and epidemiologic evidence for a strong association between NAFLD and the metabolic syndrome.
4. • Targher G, Bertolini L, Padovani R, et al.: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30: 1212-1218. This is the largest cross-sectional study assessing the prevalence rates of coronary, cerebrovascular, and peripheral vascular disease in 2839 unselected type 2 diabetic outpatients with and without NAFLD as diagnosed by liver ultrasound.
5. Marchesini G, Bugianesi E, Forlani G, et al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37: 917-923.
6. Torres DM, Harrison SA: Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008, 134: 1682-1698.
7. Villanova N, Moscatiello S, Ramilli S, et al.: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42: 473-480.
8. Schindhelm RK, Diamant M, Bakker SJ, et al.: Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005, 35: 369-374.
9. Targher G, Bertolini L, Padovani R, et al.: Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004, 27: 2498-2500.
10. Brea A, Mosquera D, Martin E, et al.: Nonalcoholic fatty liver disease is associated with carotid atherosclerosis. A case-control study. Arterioscler Thromb Vasc Biol 2005, 25: 1045-1050.
11. Volzke H, Robinson DM, Kleine V, et al.: Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005, 11: 1848-1853.
12. Fracanzani AL, Burdick L, Raselli S, et al.: Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008, 121: 72-78.
13. Targher G, Bertolini L, Padovani R, et al.: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29: 1325-1330.
14. McKimmie RL, Daniel KR, Carr JJ, et al.: Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103: 3029-3035.
15. Sookoian S, Pirola CJ: Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49: 600-607.
16. Goland S, Shimoni S, Zornitzki T, et al.: Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006, 40: 949-955.
17. Perseghin G, Lattuada G, De Cobelli F, et al.: Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47: 51-58.
18. Lin YC, Lo HM, Chen JD: Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005, 11: 4838-4842.
19. Targher G, Bertolini L, Rodella S, et al.: Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008, 51: 444-450.
20. Mirbagheri SA, Rashidi A, Abdi S, et al.: Liver: an alarm for the heart? Liver Int 2007, 27: 891-894.
21. Lautamäki R, Borra R, Iozzo P, et al.: Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291: E282-E290.
22. Schwimmer JB, Deutsch R, Behling C, Lavine JE: Fatty liver as a determinant of atherosclerosis [abstract]. Hepatology 2005, 42: 610A.
23. •• Targher G, Marra F, Marchesini G: Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51: 1947-1953. This is a comprehensive review on the relationship between NAFLD and CVD risk.
24. Adams LA, Lymp JF, St Sauver J, et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129: 113-121.
25. Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116: 1413-1419.
26. Ekstedt M, Franzen LE, Mathiesen UL, et al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44: 865-873.
27. Soderberg C, Stäl P, Askling J, et al.: Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2009, In press.
28. Ruttmann E, Brant LJ, Concin H, et al.: Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation 2005, 112: 2130-2137.
29. Lee DS, Evans JC, Robins SJ, et al.: Gamma-glutamyltransferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27: 127-133.
30. Dunn W, Xu R, Wingard DL, et al.: Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008, 103: 2263-2271.
31. Schindhelm RK, Dekker JM, Nijpels G, et al.: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191: 391-396.
32. •• Haring R, Wallaschofski H, Nauck M, et al.: Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology 2009, 50: 1403-1411. In a population-based cohort of 4160 German individuals followed up for a median period of 7. 3 years, it was shown that ultrasound-diagnosed NAFLD predicts all-cause and CVD mortality in men independently of cardiometabolic risk factors. These authors also have shown that in case of increased serum GGT levels, liver ultrasound should be performed not only for the diagnosis of NAFLD, but also for further CVD risk stratification.
33. Fraser A, Harris R, Sattar N, et al.: Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27: 2729-2735.
34. Targher G, Bertolini L, Poli F, et al.: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54: 3541-3546.
35. •• Targher G, Bertolini L, Rodella S, et al.: Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30: 2119-2121. In an outpatient cohort of 2103 type 2 diabetic individuals followed for 6. 5 years, it was shown that ultrasound-diagnosed NAFLD predicts fatal and nonfatal CVD events independently of traditional risk factors, diabetes duration, glycemic control, current use of medications, and metabolic syndrome components.
36. Targher G, Chonchol M, Bertolini L, et al.: Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008, 19: 1564-1570.
37. •• Hamaguchi M, Kojima T, Takeda N, et al.: Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007, 13: 1579-1584. In a community-based cohort of 1, 637 nondiabetic Japanese individuals followed for a mean period of 5 years, it was shown that ultrasound-diagnosed NAFLD predicts incident CVD events in both men and women independently of classical risk factors and metabolic syndrome components.
38. van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444: 875-880.
39. • Stefan N, Kantartzis K, Häring HU: Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29: 939-960. This review focuses on the mechanisms involved in the pathogenesis of hepatic fat accumulation, particularly the roles of body fat distribution, nutrition, exercise, genetics, and gene-environment interaction. Furthermore, the effects of fatty liver on glucose and lipid metabolism, specifically via induction of subclinical inflammation and secretion of humoral factors, are highlighted.
40. Korenblat KM, Fabbrini E, Mohammed BS, Klein S: Liver, muscle, and adipose tissue insulin action is directly related to intra-hepatic triglyceride content in obese subjects. Gastroenterology 2008, 134: 1369-1375.
41. Toledo FG, Sniderman AD, Kelley DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006, 29: 1845-1850.
42. Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343: 1467-1476.
43. • Targher G, Chonchol M, Miele L, et al.: Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009, 35: 277-287. This is a comprehensive review on the relationships of NAFLD with plasma inflammatory and hemostatic biomarkers.
44. Targher G, Bertolini L, Rodella S, et al.: NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16: 1394-1399.
45. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24: 29-33.
46. Hui JM, Hodge A, Farrell GC, et al.: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004, 40: 46-54.
47. Targher G, Bertolini L, Rodella S, et al.: Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 2006, 64: 679-683.
48. Xu A, Wang Y, Keshaw H, et al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112: 91-100.
49. Musso G, Gambino R, De Michieli F, et al.: Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37: 909-916.
50. Matikainen N, Mänttäri S, Westerbacka J, et al.: Postprandial lipemia associates with liver fat content. J Clin Endocrinol Metab 2007, 92: 3052-3059.